drugset
Drugs / ORIC-944
last change Apr 2026 re-read 9 days ago

ORIC-944

Small molecule targets EED via inhibition

Developed for
metastatic prostate carcinoma
Investigated by
ORIC Pharmaceuticals

Trials 1

today NCT05413421 · Ph 1
20232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05413421 Jun 2022 → Jun 2027 expected metastatic prostate carcinoma ORIC Pharmaceuticals Recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 3

DateIssuerRelease
2026-04-17 ORIC Pharmaceuticals Results ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting oricpharma.com ↗
Rinzimetostat in combination with darolutamide demonstrated antitumor activity across a breadth of in vivo models representing the prostate cancer continuum, including CSPC and CRPC.
2026-03-31 ORIC Pharmaceuticals Results ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile oricpharma.com ↗
47% of patients (7/15) achieved a PSA50 response, with 33% (5/15) confirmed.
2026-03-17 ORIC Pharmaceuticals Results ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting oricpharma.com ↗
Together, these findings suggest that targeting PRC2 with rinzimetostat re-sensitizes ARPI-resistant tumors to AR pathway inhibition and blocks prostate tumor adaptation.

All press releases naming this drug 3 releases

DateIssuerRelease

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ORIC-944 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05413421 ↗
Action Inhibit “small molecule inhibitor of PRC2” NCT05413421 ↗
Modality Small molecule “ORIC-944 is a potent, highly selective, allosteric, orally bioavailable, small molecule inhibitor of PRC2 via binding the embryonic ectoderm development (EED) subunit.” NCT05413421 ↗
Route Oral “Oral, once daily, continuous” NCT05413421 ↗
Target EED “ORIC-944 is a potent, highly selective, allosteric, orally bioavailable, small molecule inhibitor of PRC2 via binding the embryonic ectoderm development (EED) subunit.” NCT05413421 ↗